Archives
-
GSK2606414: Mapping ER Stress to Pyroptosis
2026-09-11
GSK2606414 is a selective PERK inhibitor for dissecting how ER stress connects translational control with inflammatory pyroptosis. This article converts recent nucleus pulposus cell findings into a rigorous, pharmacology-aware assay strategy for ER stress research and disease modeling.
-
Sulfo-NHS-Biotin for Functional Cell Labeling
2026-09-10
Sulfo-NHS-Biotin combines aqueous compatibility with covalent amine labeling, making it useful for intact-cell surface profiling, affinity capture, and function-linked immune-cell assays. This guide connects practical reagent handling with nanovial-based T-cell receptor discovery and provides workflow choices that help preserve specificity, viability, and downstream interpretability.
-
3D Cardiac Organoid Mapping with Shell MEAs
2026-09-10
The reference study introduces programmable, shape-adaptive shell microelectrode arrays that encase cardiac organoids and record electrical activity across three dimensions. By combining customized electrode layouts, 3D activation mapping, calcium imaging, and pharmacological challenges, the platform extends cardiac electrophysiology research beyond the planar limits of conventional MEAs.
-
Brefeldin A Workflows for ER–Golgi Stress Studies
2026-09-09
Brefeldin A enables controlled disruption of ER–Golgi trafficking, ER stress, secretion, and cancer-cell phenotypes in one experimental platform. This workflow pairs practical BFA dosing with endothelial-barrier assays inspired by a sepsis biomarker study, while clearly separating established applications from hypothesis-generating extensions.
-
1,2-Dioleoyl-sn-glycero-3-PE: Delivery Workflows
2026-09-09
Learn how DOPE supports endosomal escape, controlled liposome formulation, and more interpretable lipid-biology assays. This practical guide connects delivery optimization with the reference study on phospholipid remodeling in Magnaporthe oryzae while clearly separating established evidence from experimental hypotheses.
-
Caffeine Workflows for Cancer and Metabolism
2026-09-08
Build reproducible Caffeine assays for sarcoma cell-line inhibition, VPA combination studies, and energy-balance research. This guide connects practical stock preparation and troubleshooting with a careful, evidence-based comparison to ALDH2-focused ischemia research.
-
Ruxolitinib: Designing Mechanism-Resolved JAK Assays
2026-09-08
Ruxolitinib (INCB018424) enables selective interrogation of JAK1/2-dependent signaling in cellular models. This article presents a mechanism-resolved assay framework inspired by age-stratified inflammatory profiling, with practical guidance for myelofibrosis and oncogenic JAK2 research.
-
Actinomycin D: Reliable Cell Assay Design
2026-09-07
This scenario-driven guide explains how Actinomycin D, SKU A4448, can help researchers control transcriptional stress, apoptosis induction, and mRNA stability workflows. It covers mechanism, solvent compatibility, concentration selection, interpretation, and practical vendor-selection criteria for reproducible cell-based assays.
-
DiscoveryProbe Natural Product Library Plus
2026-09-07
DiscoveryProbe Natural Product Library Plus is a 1,655-compound natural product library for high throughput screening and high content screening. Its DMSO-pre-dissolved format and documented analytical quality support reproducible natural product screening for drug discovery, while Cryptosporidium AdhE findings provide a target-based rationale for follow-up assays rather than proof of product-specific efficacy.
-
Q-VD-OPh as a Mechanistic Apoptosis Probe
2026-09-05
Q-VD-OPh is a cell-permeable pan-caspase inhibitor for dissecting caspase activity inhibition from upstream mitochondrial remodeling. This article translates LACTB–mitochondria findings into practical assay strategies for apoptosis research, neurodegeneration studies, and cell-survival workflows.
-
AAL-993 and the Next Logic of Tumor Angiogenesis
2026-09-04
A mechanistic and translational perspective on how AAL-993 can clarify VEGF receptor biology, strengthen tumor angiogenesis research, and complement pathway-level studies such as Shenqi Fuzheng injection research in glioma.
-
AG-221 Enasidenib Workflows for IDH2 AML
2026-09-04
Build more informative IDH2-mutant AML assays by pairing AG-221-driven 2-hydroxyglutarate reduction with metabolic, epigenetic, and differentiation readouts. This workflow also shows how CD44-associated metabolic rewiring can be tested as a complementary vulnerability rather than treated as a substitute for mutant IDH2 inhibition.
-
Biomimetic Chromatography for Lung Permeability
2026-09-03
A 2025 International Journal of Pharmaceutics study compares IAM-LC and phospholipid-coated OT-CEC, both coupled with mass spectrometry, as biomimetic models of pulmonary drug permeability. Its results show that IAM-LC offers strong quantitative alignment with permeability and conventional lipophilicity metrics, while OT-CEC adds complementary information about phospholipid-specific interactions.
-
Latrunculin B: Reliable Actin Assay Workflows
2026-09-03
This scenario-driven guide explains how Latrunculin B, SKU C5804, can improve interpretation of viability, proliferation, and cytoskeletal assays when actin remodeling is an experimental variable. It combines mechanism, preparation guidance, assay controls, literature context, and practical supplier-selection criteria for reproducible short-term studies.
-
CGP 55845 hydrochloride for GABAB Assays
2026-09-02
CGP 55845 hydrochloride provides a controlled way to test how GABAB signaling shapes presynaptic release, astrocyte calcium responses, and synaptic plasticity. This workflow translates dentate gyrus findings on astrocytic GAT-3 into practical in vitro neurotransmission assay designs while separating receptor effects from transporter-mediated mechanisms.